CV Issue 2 2018

CORPORATE VISION / Issue 2 2018 47 , Endoceutics is a private pharmaceutical company operating in the field of women’s health and hormone-sensitive cancer prevention and treatment.We profile the firmand speak to founder, Fernand Labrie, who provides us with an insight into the company’s ongoing success. Healthy Aging Endoceutics was founded by Dr. Fernand Labrie, who previously discovered and developed medical castration with GnRH agonists and combined androgen blockade, the first treatment shown to prolong life in prostate cancer. Endoceutics is considered a world leader in the mechanism of action of sex steroids and control of their action. Following approval of IntrarosaTM by the FDA in November 2016 for the treatment of dyspareunia, a predominant symptom of vulvovaginal atrophy due to menopause, Endoceutics focuses on developing non estrogen-based therapies for sexual dysfunction and other symptoms of menopause, including hot flushes, osteoporosis and muscle loss. Hormonal therapies for breast, uterine and prostate cancer, as well as male hypogonadism and endometriosis are also under development. Fernand outlines the firm’s overall mission, explaining what steps the team are planning to take in order to ensure targets are reached. There is a strong desire within the company to move science forward in regard to how women feel when they grow older, as Fernand describes. “Contributing to women healthcare, our overall aim is to be able to offer to all women around the world the benefits of an efficacious and safe treatment of all the problems of menopause, which include hot flushes, vaginal dryness, sexual dysfunction, loss of bone, loss of muscle as well as memory and cognition loss. We have a strong desire to move science forward for a better life of our fellow citizens, and this will remain our ongoing goal.” Famously, the healthcare industry can be incredibly competitive and so it is vital that companies revolutionise their products and are constantly innovating their services. Fernand tells us what it is specifically that helps Endoceutics stand out from the crowd. “In addition to the discovery of medical castration and combined androgen blockade which have become the standard treatment of prostate cancer which continues to help millions of men worldwide, there are 32 million women in the United States alone who could benefit from IntrarosaTM, the newly discovered and developed treatment of vulvovaginal atrophy approved in November 2016 by the FDA. IntrarosaTM is the first physiological non-estrogenic treatment for vulvovaginal atrophy. This treatment uses Prasterone (DHEA), a compound without intrinsic estrogenic or androgenic activity which is transformed intracellularly into androgens and estrogens only in the cells and vaginal layers physiologically in need of these sex steroids. This innovative treatment provides a replacement for the local deficiency in sex steroids with no significant increase in circulating estrogens or androgens and consequently, no effect in the other tissues. “Furthermore, positive effects are observed on the four domains of sexual dysfunction, namely desire, arousal, orgasm and pleasure, an effect secondary to local androgen formation and not found with estrogens. These observations are under further evaluation by Endoceutics.” Having alluded to how the firm distinguishes itself apart from others in the healthcare industry, Fernand goes into further detail about what techniques are employed within the company which enable it to stay ahead of emerging developments. “In order to keep ahead of this field, we will be exploring more clinical applications using the best technology which we largely developed, taking as example the mass spectrometry-based steroid assays, which have become the gold standard in the industry. Change in the therapeutic domain is central to improving the lives of women across the globe, and as such, we will continue to embrace this strategy as we seek to be the leaders of innovation in women’s health in the pharmaceutical market.” Overall, there looks to be a very exciting future ahead for Endoceutics, with the company believing that the female health market will come to be dominated by a focus on innovative, creative 1711CV23 and long-lasting treatments for all aspects of menopause based upon Intracrinology. Intracrinology is a discovery of Professor Labrie’s team first applied to prostate cancer treatment and now at the basis of Intrarosa TM for the treatment of vulvovaginal atrophy. Moving forward, Endoceutics, Inc. foresees exciting times ahead as it seeks to bring Intrarosa TM to market and potentially change the lives of millions of women around the world. In his concluding comments, Fernand stresses that it is essential that there is support from people in Canada regarding science, as the company continues towards its mission of changing healthcare for the better, which in turn benefits the global population. “Ultimately, it is extremely important for Canada to give strong support to the science at all levels, the best if not the only way to support and develop a competitive economy and optimise the life and quality of life of all Canadians.” Contact: Fernand Labrie Address: 2795 Laurier Blvd, Suite 500, Quebec, G1V 4M7, Canada Phone: 418 653 0033 Website: www.endoceutics.com

RkJQdWJsaXNoZXIy NTY1MjI4
http://www.currencymatters.co.uk/ http://www.endoceutics.com/ http://www.paccsinc.com/ http://www.seaslex.it/